Oncolytics Announces Positive Top Line REOLYSIN Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers
December 13, 2012 at 06:34 AM EST
Oncolytics Biotech (NASDAQ: ONCY ) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018). The endpoint examines initial percentage tumour